Niaid SPF macaque breeding colonies

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N93024D00044
Awardee
Awarding agency
Task orders
4 $24,768,855 obligated

Award facts

Opportunity
Combined order value
  • $24,768,855 Current, with exercised options
  • $25,168,855 Potential, with all options
Last date to order 30% complete
IDV ceiling 52% used
$48,000,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Alpha Genesis Inc., a for-profit Subchapter S Corporation, to provide specific pathogen free (SPF) nonhuman primate breeding colonies in support of NIAID's research programs. Under this IDIQ contract, two delivery orders have been issued to date: one for $8,046,548 to maintain and expand NIAID's SPF macaque breeding colonies through September 2025, and another for $221,664 to fund the continued operation and upkeep of NIAID's macaque breeding colonies through September 2031. Alpha Genesis has previously provided nonhuman primates, associated services, and maintenance of breeding colonies to NIAID and other federal agencies through similar contract vehicles. The original solicitation indicates NIAID has a requirement for the maintenance, care, breeding, and management of government-owned SPF Mauritian cynomolgus macaque and Indian-origin rhesus macaque colonies to support translational research related to infectious diseases, immunology, and organ transplantation.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N93024D00044?

75N93024D00044 was awarded to Alpha Genesis Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2024.

How much is contract 75N93024D00044 worth?

Orders under 75N93024D00044 have obligated $24,768,855. Their combined potential value, with all options, is $25,168,855. 75N93024D00044's own ceiling is $48,000,000.

How many orders have been placed under contract 75N93024D00044?

4 orders have been placed under 75N93024D00044, the latest on September 30, 2026.

Who can order from contract 75N93024D00044?

75N93024D00044 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N93024D00044 competed?

The extent of competition for 75N93024D00044 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV